加载中
Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland. Its flagship product, the TULSA-PRO system, is specifically designed for use with magnetic resonance imaging (MRI) scanners within hospital settings and other treatment centers. Additionally, Profound Medical offers Sonalleve, a therapeutic platform that addresses uterine fibroids – including through non-invasive methods – and provides palliative relief for pain linked to bone metastases. The company's primary operations are headquartered in Mississauga, Canada.
前收盘价
US$6.90
−US$0.01 · -0.14%
盘中时间采用ET。市场数据可能有所延迟。
Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland. Its flagship product, the TULSA-PRO system, is specifically designed for use with magnetic resonance imaging (MRI) scanners within hospital settings and other treatment centers. Additionally, Profound Medical offers Sonalleve, a therapeutic platform that addresses uterine fibroids – including through non-invasive methods – and provides palliative relief for pain linked to bone metastases. The company's primary operations are headquartered in Mississauga, Canada.
日内区间
当前US$6.90
52周区间
当前US$6.90
盘中时间采用ET。市场数据可能有所延迟。
Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland. Its flagship product, the TULSA-PRO system, is specifically designed for use with magnetic resonance imaging (MRI) scanners within hospital settings and other treatment centers. Additionally, Profound Medical offers Sonalleve, a therapeutic platform that addresses uterine fibroids – including through non-invasive methods – and provides palliative relief for pain linked to bone metastases. The company's primary operations are headquartered in Mississauga, Canada.
日内区间
当前US$6.90
52周区间
当前US$6.90
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1637.98万 USD | 1016.72万 USD | 719.9万 USD | 668.1万 USD | 687.3万 USD |
| 销货成本 | 478.74万 USD | 346.81万 USD | 281.7万 USD | 366万 USD | 392.1万 USD |
| 毛利 | 1159.24万 USD | 669.91万 USD | 438.2万 USD | 302.1万 USD | 295.2万 USD |
| 研究与开发 | 2095.65万 USD | 1615.04万 USD | 1437.7万 USD | 1469万 USD | 1527.7万 USD |
| 销售、一般及管理费用 | 3261.21万 USD | 2202.33万 USD | 1862.1万 USD | 1793.3万 USD | 1796.6万 USD |
| 营业费用 | 5356.86万 USD | 3817.37万 USD | 3299.8万 USD | 3514.7万 USD | 3324.3万 USD |
| 利息收入 | 108.87万 USD | 136.71万 USD | 164.2万 USD | 104.97万 USD | 20.32万 USD |
| 利息支出 | — | — | 77万 USD | 16.71万 USD | 6.64万 USD |
| 折旧和摊销 | 56.98万 USD | 93.6万 USD | 92.9万 USD | 160.4万 USD | 187.9万 USD |
| 营业利润 | −4197.62万 USD | −3147.46万 USD | −2861.6万 USD | −3212.6万 USD | −3029.1万 USD |
| 净利润 | −4331.52万 USD | −2648.05万 USD | −2856.9万 USD | −2866.9万 USD | −3069.9万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2019年10月16日 | 1:10 | — | — |
已生效 2019年10月16日
1:10
报告持有此股票敞口的交易所交易基金。
Invesco NASDAQ Future Gen 200 ETFQQQS
Dimensional - International Core Equity 2 ETFDFIC
State Street SPDR Portfolio Europe ETFSPEUAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
